Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapy.

@article{Tefferi2006RespectiveCO,
  title={Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapy.},
  author={Ayalew Tefferi and Jacob J Strand and Terra L. Lasho and Michelle A Elliott and C Y Li and Ruben A. Mesa and Gordon W. Dewald},
  journal={Cancer},
  year={2006},
  volume={106 8},
  pages={1739-43}
}
BACKGROUND Patients who have myelofibrosis with myeloid metaplasia (MMM) display recurrent, albeit nonspecific cytogenetic abnormalities that are diverse prognostically. For the current study, the authors explored the relation between specific cytogenetic clones and JAK2(V617F) mutational status in patients with MMM and the effects on treatment response to erythropoietin (Epo). METHODS Concomitantly collected blood granulocytes and bone marrow were processed for JAK2(V617F) mutation analysis… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

From palliation to epigenetic therapy in myelofibrosis.

Hematology. American Society of Hematology. Education Program • 2008
View 1 Excerpt

Biology and treatment of primary myelofibrosis.

Hematology. American Society of Hematology. Education Program • 2007
View 1 Excerpt

Similar Papers

Loading similar papers…